Sanofi Stock Ignites Turbo Boost Following Stifel Recommendation

The investment bank Stifel has upgraded its rating of Sanofi stock from "Hold" to "Buy" and has raised the stock price target from 95 to 109 euros. Analyst Eric Le Berrigaud anticipates that the French pharmaceutical company will achieve double-digit growth by the year 2027, a prospect about which he expresses no doubt in a recently published study. According to Le Berrigaud, Sanofi will particularly benefit from increased efficiency in the research sector following this growth phase. Given the current price level of the stock, the expert identifies hardly any significant risks that would argue against an investment – on the contrary, he sees favorable opportunities for initial engagements in the stock market. Therefore, Stifel Bank's recommendation could be the signal for an upward trend in the Sanofi stock, which is likely to pique the interest of investors.